BACKGROUND: The association between HRQL measures with outcomes in patients with metastatic hormone-refractory prostate cancer (HRPC) is unclear. METHODS: Baseline and 12-week HRQL was collected using the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy - Prostate (FACT-P). Outcomes included: (1) survival; (2) time to disease progression and (3) time to bone pain. Cox proportional hazards regression models were used. The relative predictive performance of each HRQL instrument and domain was compared. RESULTS: Baseline HRQL scores and 12-week change scores > the median were significant predictors of all clinical outcomes but varied by domain. For example, the hazard of death for a change in FACT-P Grand Total Score > median was 49% of the hazard for a change < or = the median. Including baseline or 12-week change in HRQL resulted in improvement in prediction performance. CONCLUSIONS: Patients with better baseline HRQL have better predicted survival, time to disease progression and pain prognosis than those with worse HRQL. In addition, the 12-week change in HRQL appears to improve predictive accuracy for most clinical outcomes. It appears that greater deterioration in HRQL is prognostic for rapid disease progression.
BACKGROUND: The association between HRQL measures with outcomes in patients with metastatic hormone-refractory prostate cancer (HRPC) is unclear. METHODS: Baseline and 12-week HRQL was collected using the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy - Prostate (FACT-P). Outcomes included: (1) survival; (2) time to disease progression and (3) time to bone pain. Cox proportional hazards regression models were used. The relative predictive performance of each HRQL instrument and domain was compared. RESULTS: Baseline HRQL scores and 12-week change scores > the median were significant predictors of all clinical outcomes but varied by domain. For example, the hazard of death for a change in FACT-P Grand Total Score > median was 49% of the hazard for a change < or = the median. Including baseline or 12-week change in HRQL resulted in improvement in prediction performance. CONCLUSIONS:Patients with better baseline HRQL have better predicted survival, time to disease progression and pain prognosis than those with worse HRQL. In addition, the 12-week change in HRQL appears to improve predictive accuracy for most clinical outcomes. It appears that greater deterioration in HRQL is prognostic for rapid disease progression.
Authors: P Schellhammer; A Cockett; L Boccon-Gibod; M Gospodarowicz; A Krongrad; I M Thompson; P Scardino; M Soloway; J Adolfsson Journal: Urology Date: 1997-04 Impact factor: 2.649
Authors: A Coates; D Thomson; G R McLeod; P Hersey; P G Gill; I N Olver; R Kefford; R M Lowenthal; G Beadle; E Walpole Journal: Eur J Cancer Date: 1993 Impact factor: 9.162
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: C L Loprinzi; J A Laurie; H S Wieand; J E Krook; P J Novotny; J W Kugler; J Bartel; M Law; M Bateman; N E Klatt Journal: J Clin Oncol Date: 1994-03 Impact factor: 44.544
Authors: M J Moore; D Osoba; K Murphy; I F Tannock; A Armitage; B Findlay; C Coppin; A Neville; P Venner; J Wilson Journal: J Clin Oncol Date: 1994-04 Impact factor: 44.544
Authors: Barbara Deschler; Gabriele Ihorst; Uwe Platzbecker; Ulrich Germing; Eva März; Marcelo de Figuerido; Kurt Fritzsche; Peter Haas; Helmut R Salih; Aristoteles Giagounidis; Dominik Selleslag; Boris Labar; Theo de Witte; Pierre Wijermans; Michael Lübbert Journal: Haematologica Date: 2012-08-08 Impact factor: 9.941
Authors: Angeles A Secord; Robert L Coleman; Laura J Havrilesky; Amy P Abernethy; Gregory P Samsa; David Cella Journal: Nat Rev Clin Oncol Date: 2015-03-10 Impact factor: 66.675
Authors: Mark van Heijl; Mirjam A G Sprangers; Angela G E M de Boer; Sjoerd M Lagarde; Hans B Reitsma; Olivier R C Busch; Hugo W Tilanus; Jan J B van Lanschot; Mark I van Berge Henegouwen Journal: Ann Surg Oncol Date: 2009-10-15 Impact factor: 5.344